Research Site

North Little Rock, Arkansas 72117

1 studies enrolling now · 12 studies all time

What they study most

Acute Coronary Syndrome, COPD, Celiac Disease, Constipation-Predominant Irritable Bowel Syndrome, Dyspepsia, GERD, GERD With Erosive Esophagitis, GERD Without Erosive Esophagitis, Helicobacter Pylori Infection, Irritable Bowel Syndrome With Constipation (IBS-C), Opioid-Induced Constipation, Opioid-Induced Constipation (OIC)

Studies at this site

• Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — Recruiting now
• Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms — Stopped early
• Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) — Completed
• ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator — Completed
• A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) — Completed
• Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation — Completed
• Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain — Stopped early
• Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation — Completed
• A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis. — Completed
• A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis. — Completed
• An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) — Completed
• Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C) — Stopped early